For how we live.
The LEAP trial found that feeding peanut to high-risk babies from infancy cut peanut allergy at age five from 13.7% to 1.9%. A follow-up showed the protection held — but high-risk infants should be assessed first.
Xerosis is a barrier problem, not dirt. Cochrane found moisturisers cut eczema flares 60% and spared steroid use; in care-home residents a twice-daily emollient roughly halved skin tears, on weak evidence.
Two birth cohorts totalling 9,801 children were sorted into eight developmental patterns. The classic progression was one of them, and one of the smallest.
Rezpegaldesleukin works by expanding the immune system's regulatory T cells rather than blocking an inflammatory signal — a new mechanism for atopic dermatitis, tested so far only in a phase 2b study.
A large randomised promotion trial and sibling studies find some real benefits in infancy — fewer gut infections, less eczema — but the sweeping long-term advantages shrink once confounding is accounted for.
The LEAP trial cut peanut allergy in high-risk infants from 13.7% to 1.9%. A second trial found the benefit real but harder to achieve — and only in children who actually ate the food.
The LEAP trial reversed a generation of avoidance advice. A second trial run in the general population missed its primary endpoint, and the distance between those two results is the part usually left out.